JPMorgan likes Otonomy, sees almost 50% upside; shares ahead 11%
Aug. 15, 2017 10:56 AM ET|About: Otonomy (OTIC)|By: Douglas W. House, SA News Editor
•Thinly traded small cap Otonomy (OTIC +10.8%) perks up on average volume on the heels of a bullish call from JPMorgan. Analyst Anupam Rama believes the stock could rally as much as 95% on positive results from the clinical trial evaluating Otividex for Meniere's disease. Top-line data should be available next month (OVERWEIGHT/$28).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.